Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

Kevin Windebank, Tom Walwyn, Richard Kirk, Gareth Parry, Asif Hasan, Nick Bown, Bridget Wilkins

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.

Original languageEnglish (US)
Pages (from-to)392-396
Number of pages5
JournalPediatric Blood and Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 1 2009

Fingerprint

Burkitt Lymphoma
Lymphoproliferative Disorders
Heart Transplantation
Human Herpesvirus 4
Transplants
Drug Therapy
Leukemia
Combination Drug Therapy
Allografts
Lymphoma
Rituximab
Therapeutics

Keywords

  • Burkitt lymphoma
  • Epstein-Barr virus
  • Immunocompromised host
  • Immunotherapy
  • Transplantation
  • Tumour biology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. / Windebank, Kevin; Walwyn, Tom; Kirk, Richard; Parry, Gareth; Hasan, Asif; Bown, Nick; Wilkins, Bridget.

In: Pediatric Blood and Cancer, Vol. 53, No. 3, 01.09.2009, p. 392-396.

Research output: Contribution to journalArticle

Windebank, Kevin ; Walwyn, Tom ; Kirk, Richard ; Parry, Gareth ; Hasan, Asif ; Bown, Nick ; Wilkins, Bridget. / Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 3. pp. 392-396.
@article{a32496031e9a4d14875921aa8a0a4550,
title = "Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab",
abstract = "Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.",
keywords = "Burkitt lymphoma, Epstein-Barr virus, Immunocompromised host, Immunotherapy, Transplantation, Tumour biology",
author = "Kevin Windebank and Tom Walwyn and Richard Kirk and Gareth Parry and Asif Hasan and Nick Bown and Bridget Wilkins",
year = "2009",
month = "9",
day = "1",
doi = "10.1002/pbc.22070",
language = "English (US)",
volume = "53",
pages = "392--396",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

AU - Windebank, Kevin

AU - Walwyn, Tom

AU - Kirk, Richard

AU - Parry, Gareth

AU - Hasan, Asif

AU - Bown, Nick

AU - Wilkins, Bridget

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.

AB - Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.

KW - Burkitt lymphoma

KW - Epstein-Barr virus

KW - Immunocompromised host

KW - Immunotherapy

KW - Transplantation

KW - Tumour biology

UR - http://www.scopus.com/inward/record.url?scp=67651216263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651216263&partnerID=8YFLogxK

U2 - 10.1002/pbc.22070

DO - 10.1002/pbc.22070

M3 - Article

C2 - 19459198

AN - SCOPUS:67651216263

VL - 53

SP - 392

EP - 396

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -